|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
46,110,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile BioAtla is a biopharmaceutical company engaged in developing specific and selective antibody-based therapeutics for the treatment of various cancers. Co.'s lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types. Co. also develops BA3021, a CAB ADC for NSCLC and Melanoma; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
81,495 |
83,495 |
252,735 |
| Total Buy Value |
$0 |
$172,540 |
$177,620 |
$814,041 |
| Total People Bought |
0 |
4 |
4 |
4 |
| Total Buy Transactions |
0 |
4 |
5 |
15 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-18 |
2023-10-17 |
2023-04-18 |
2022-04-18 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Smith Scott Andrew |
|
– • – |
2024-03-31 |
4 |
D |
$3.44 |
$7,503 |
D/D |
(2,181) |
292,455 |
|
- |
|
| Sievers Eric |
Chief Medical Officer |
• – – |
2024-03-31 |
4 |
D |
$3.44 |
$1,968 |
D/D |
(572) |
210,422 |
|
- |
|
| Smith Scott Andrew |
Director |
– • – |
2024-02-29 |
4 |
D |
$2.70 |
$5,889 |
D/D |
(2,181) |
294,636 |
|
- |
|
| Sievers Eric |
Chief Medical Officer |
• – – |
2024-02-29 |
4 |
D |
$2.70 |
$1,544 |
D/D |
(572) |
210,994 |
|
- |
|
| Short Jay M Phd |
Chief Executive Officer |
• • • |
2024-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
417,000 |
1,856,283 |
|
- |
|
| Waldron Richard A |
Chief Financial Officer |
• – – |
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
106,000 |
230,923 |
|
- |
|
| Vasquez Christian |
See Remarks |
• – – |
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
70,000 |
185,659 |
|
- |
|
| Sievers Eric |
Chief Medical Officer |
• – – |
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
122,000 |
211,566 |
|
- |
|
| Sievers Eric |
Chief Medical Officer |
• – – |
2024-01-31 |
4 |
D |
$1.92 |
$1,261 |
D/D |
(657) |
89,566 |
|
- |
|
| Smith Scott Andrew |
Director |
– • – |
2024-01-31 |
4 |
D |
$1.92 |
$4,188 |
D/D |
(2,181) |
296,817 |
|
- |
|
| Smith Scott Andrew |
Director |
– • – |
2023-12-31 |
4 |
D |
$2.46 |
$4,406 |
D/D |
(1,791) |
298,998 |
|
- |
|
| Sievers Eric |
Chief Medical Officer |
• – – |
2023-12-31 |
4 |
D |
$2.46 |
$1,365 |
D/D |
(555) |
90,223 |
|
- |
|
| Gray Mary Ann |
Director |
– • – |
2023-12-31 |
4 |
A |
$0.00 |
$0 |
D/D |
5,995 |
37,397 |
|
- |
|
| Williams Eddie |
Director |
– • – |
2023-12-31 |
4 |
A |
$0.00 |
$0 |
D/D |
4,827 |
20,200 |
|
- |
|
| Mcbrinn Sylvia |
Director |
– • – |
2023-12-26 |
4 |
B |
$2.33 |
$9,320 |
D/D |
4,000 |
15,125 |
2.39 |
- |
|
| Short Jay M Phd |
Chief Executive Officer |
• • • |
2023-12-20 |
4 |
B |
$2.14 |
$106,910 |
D/D |
50,000 |
1,439,283 |
3.23 |
- |
|
| Vasquez Christian |
See Remarks |
• – – |
2023-12-19 |
4 |
B |
$2.04 |
$15,262 |
D/D |
7,495 |
115,659 |
2.74 |
- |
|
| Steinman Lawrence |
Director |
– • – |
2023-12-19 |
4 |
B |
$2.05 |
$41,048 |
D/D |
20,000 |
38,459 |
2.39 |
- |
|
| Sievers Eric |
Chief Medical Officer |
• – – |
2023-11-30 |
4 |
D |
$1.77 |
$981 |
D/D |
(554) |
90,778 |
|
- |
|
| Smith Scott Andrew |
Director |
– • – |
2023-11-30 |
4 |
D |
$1.77 |
$3,170 |
D/D |
(1,791) |
300,789 |
|
- |
|
| Waldron Richard A |
Chief Financial Officer |
• – – |
2023-10-31 |
4 |
D |
$1.47 |
$1,426 |
D/D |
(970) |
124,923 |
|
- |
|
| Short Jay M Phd |
Chief Executive Officer |
• • • |
2023-10-31 |
4 |
D |
$1.47 |
$4,245 |
D/D |
(2,888) |
1,389,283 |
|
- |
|
| Vasquez Christian |
See Remarks |
• – – |
2023-10-31 |
4 |
D |
$1.47 |
$285 |
D/D |
(194) |
101,162 |
|
- |
|
| Smith Scott Andrew |
Director |
– • – |
2023-10-31 |
4 |
D |
$1.47 |
$2,633 |
D/D |
(1,791) |
302,580 |
|
- |
|
| Sievers Eric |
Chief Medical Officer |
• – – |
2023-10-31 |
4 |
D |
$1.47 |
$816 |
D/D |
(555) |
91,332 |
|
- |
|
207 Records found
|
|
Page 1 of 9 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
